Cited by 532Alzheimer's disease research and treatmentsGenetic Associations and EpidemiologyDementia and Cognitive Impairment Research

Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes

Open access
Schwartzentruber, Jeremy, Cooper, Sarah, Liu, Jimmy Z., Barrio-Hernandez, Inigo, Bello, Erica, Kumasaka, Natsuhiko, Young, Adam M. H., Franklin, Robin J. M. +5 more·2021·Nature Genetics

Published version of a preprint

Abstract

Genome-wide association studies have discovered numerous genomic loci associated with Alzheimer's disease (AD); yet the causal genes and variants are incompletely identified. We performed an updated genome-wide AD meta-analysis, which identified 37 risk loci, including new associations near CCDC6, TSPAN14, NCK2 and SPRED2. Using three SNP-level fine-mapping methods, we identified 21 SNPs with >50% probability each of being causally involved in AD risk and others strongly suggested by functional annotation. We followed this with colocalization analyses across 109 gene expression quantitative trait loci datasets and prioritization of genes by using protein interaction networks and tissue-specific expression. Combining this information into a quantitative score, we found that evidence converged on likely causal genes, including the above four genes, and those at previously discovered AD loci, including BIN1, APH1B, PTK2B, PILRA and CASS4.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-020-00776-w

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nine loci (APP, CCDC6, GRN, LILRB2, NCK2, TNIP1, TMEM106B, TSPAN14 and SHARPIN) were recently reported in three articles using part of the GWAS data included in the study.

    “Nine of these loci (APP, CCDC6, GRN, LILRB2, NCK2, TNIP1, TMEM106B, TSPAN14 and SHARPIN) were recently reported in three articles using part of the GWAS data included in our study11–13.”

    From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [11]

    The Results section (“Meta-analysis discovers 37 loci associated with Alzheimer’s disease risk”; page unavailable) identifies several listed loci and describes overlap with earlier GWAS reports. It does not establish that all nine named loci were reported in three articles using part of the citing study’s GWAS data. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Microglia are implicated in the pathology and genetic risk of several central nervous system diseases, including Alzheimer's disease.

    “Microglia, the resident immune cells of the brain, are implicated in the pathology and genetic risk of several CNS diseases, including AD.46,47,48,49”

    From hdWGCNA identifies co-expression networks in high-dimensional transcriptomics data (2023) · cites this paper as [48]

    The Results section (‘AD risk is enriched near genes with high microglial gene expression’; page not provided) reports enrichment of Alzheimer’s disease risk near genes highly expressed in microglia. The paper also discusses a possible role for microglial activation in AD, but the passages do not extend that finding to several CNS diseases. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Independent association signals detected in the CD33, HLA, PICALM and RHOH loci are new compared to refs. 4-6,9.

    “Compared to refs. 4–6,9, the independent association signals detected in the CD33, HLA, PICALM and RHOH loci are new”

    From Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias (2026) · cites this paper as [9]

    The Results section ('Meta-analysis discovers 37 loci associated with Alzheimer’s disease risk'; page unavailable) reports independent signals at several loci, supporting the general finding. It does not identify CD33, HLA, PICALM and RHOH as loci with new independent signals or establish their novelty relative to refs. 4–6,9. The Discussion’s four novel associations concern different loci and do not resolve that comparison. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Several AD GWAS loci implicate B cell relevant genes including SCIMP, BLNK, PLCG2, HLA class II region and IGHG1.

    “Indeed, several AD GWAS loci implicate B cell relevant genes as well, albeit with varying strength of evidence and confidence in causal gene assignment. These include SCIMP , BLNK , PLCG2 , HLA class II region and IGHG1 [26 -32].”

    From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [29]

    The Results (pages unavailable) identify PLCG2 among AD genes supported by network scores and report an AD-associated locus near IGHG1. The Online Methods also discuss an HLA locus, but the passages do not identify it as a class II signal. Our copy does not substantiate the inclusion of SCIMP or BLNK, or characterize these loci as B-cell-relevant. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • HLA class II locus encompassing HLA-DRB1/HLA-DQA1 is a well established AD risk locus, although extensive linkage disequilibrium makes it difficult to pin down the specific causal gene.

    “The HLA class II locus encom­ passing HLA-DRB1/HLA-DQA1 is also a well established AD risk locus, although extensive linkage disequilibrium across this region makes it difficult to pin down the specific causal gene.”

    From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [29]

    The Online Methods treat HLA as an AD risk locus, and Extended Data Fig. 2 cautions that its fine-mapping results should be interpreted carefully. But our copy does not identify the locus as encompassing HLA-DRB1/HLA-DQA1 or say that extensive LD across that region prevents identification of the causal gene; the fine-mapping discussion instead points to sensitivity to the reference panel. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [53]Alasoo K Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response Nat Genet 2018 50 424 431 29379200 PMC6548559

Cited by

Sorted by citations

Authors
Schwartzentruber, J., Cooper, S., Liu, J. Z., Barrio-Hernandez, I., Bello, E., Kumasaka, N., Young, A. M. H., Franklin, R. J. M., Johnson, T., Estrada, K., Gaffney, D. J., Beltrao, P., & Bassett, A.
Affiliations
  • European Bioinformatics Institute (GB)
  • Wellcome Sanger Institute (GB)
  • Biogen (United States) (US)
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
  • GlaxoSmithKline (United Kingdom) (GB)
  • BioMarin (United States) (US)
Corresponding author
  • Schwartzentruber, Jeremy
  • Bassett, Andrew
Venue
Nature Genetics
Published
2021-02-15
Volume
53
Issue
3
Pages
392-402
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W3115346491
Cited by
532
References
128
Citations by year
2026: 75 · 2025: 105 · 2024: 117 · 2023: 96 · 2022: 86 · 2021: 50 · 2020: 3
FWCI
56.94
Type
journal article
Language
en
Open access
Locations
  • Nature Genetics (publishedVersion)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • Multiple Sclerosis Society (50)
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • Wellcome Trust (203151/Z/16/Z, PhD for clinicians fellowship)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, genetic susceptibility loci, causal variant identification, fine mapping, colocalization, expression quantitative trait loci, protein-protein interaction network, tissue-specific gene expression, CCDC6, Nck2, SPRED2, BIN1, Pyk2, susceptibility genes
MeSH terms
Alzheimer Disease, Chromosome Mapping, Cytoskeletal Proteins, Humans, Risk Factors, Oncogene Proteins, Linkage Disequilibrium, Gene Expression, Microglia, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Quantitative Trait Loci, Adaptor Proteins, Signal Transducing, Genome-Wide Association Study, Tetraspanins, Protein Interaction Maps

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review